<DOC>
	<DOCNO>NCT02539134</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( PK ) multiple rise dos TAK-935 healthy participant .</brief_summary>
	<brief_title>TAK-935 Multiple Rising Dose Study Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-935 . This study look pharmacokinetics , safety tolerability TAK-935 healthy participant . The study enroll approximately 56 participant . Participants randomly assign ( chance , like flip coin ) 1 5 cohort Part 1 , remain undisclosed participant study doctor study ( unless urgent medical need ) : • Part 1 , Cohort 1 : TAK-935 100 mg daily ( QD ) • Part 1 , Cohort 2 : TAK-935 300 mg QD• Part 1 , Cohort 3 : TAK-935 300 mg twice daily ( BID ) • Part 1 , Cohort 4 : TAK-935 600 mg QD • Part 1 , Cohort 5 : TAK-935 900 1350 mg QD . Participants ask take oral solution twice day time 14 day . An optional Part 2 may conduct collect data assess engagement TAK-935 central molecular target cholesterol 24S-hydroxylase ( CH24H ) measure change level metabolite 24S-hydroxycholesterol ( 24HC ) . In Part 2 , participant assign 2 treatment group dos base data ongoing TAK-935 trial , combine safety tolerability data Cohorts 1-4 Part 1 . This single center trial conduct United States . The overall time participate study approximately 30 day . Participants admit clinic first 14 day , contact telephone Day 28 follow-up assessment .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>All Cohorts 1 . Is capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure include request subject fast laboratory evaluation . 3 . Is healthy male female age 18 55 year inclusive , time informed consent first study medication dose . 4 . Weighs least 45 kilogram ( kg ) body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening Day 1 . 5 . Male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 6 . Female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study , 30 day last dose . 7 . Can complete CogState Battery Screening . Additional Inclusion Criteria Subjects undergoing cerebrospinal fluid ( CSF ) Sampling ( Part 2 ) : 8 . Agrees spinal tap procedure CSF collection . All Cohorts 1 . Has receive investigational compound within 30 day prior randomization . 2 . Has receive TAK935 previous clinical study therapeutic agent . 3 . Has significant history uncontrolled , clinically significant neurologic ( include seizure disorder ) , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine disease psychiatric disorder endocrine disease abnormality significant result physical examination , clinical laboratory result may impact ability subject participate potentially confound study result . It responsibility investigator assess clinical significance ; however , consultation Takeda Medical Monitor may warrant . 4 . Has know hypersensitivity component formulation TAK935 . 5 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1year prior screen visit unwilling agree abstain alcohol drug throughout study . One unit equivalent halfpint beer single measure spirit 1 small glass wine . 6 . Has take exclude medication , supplement , food product time period list Excluded Medications Dietary Products table . Additional Exclusion Criteria Subjects undergo CSF sampling ( Part 2 ) 7 . Has CSF collection perform within 30 day prior checkin ( Day 3 ) . 8 . Has know hypersensitivity anesthetic derivative use CSF collection , medication use prepare area lumbar puncture . 9 . Has significant vertebral deformity ( scoliosis kyphosis ) , opinion investigator , may interfere lumbar puncture procedure . 10 . Has history clinically significant back pain and/or injury . 11 . Has local infection puncture site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>